Scientific basis of B-cell modulation for anti-tumor immunity and reduction of ICI toxicity: A Deep

When:  Sep 15, 2022 from 12:00 to 14:00 (CT)
This webinar, the fifth of the 2022 Targets for Cancer IO: A Deep Dive Series, will discuss the research and clinical findings behind B-cell modulation for anti-tumor immunity and reduction of ICI toxicity. Basic, clinical and translational researchers in academia and industry and members of the investment community are the target audience of this series.

Moderators:
  • Tullia C. Bruno, PhD – University of Pittsburgh
  • Daniel Hollern, PhD – The Salk Institute for Biological Studies
Faculty:
  • Karen WIllard-Gallo, PhD - Institut Jules Bordet
  • Yuliya Pylayeva-Gupta, PhD - UNC at Chapel Hill
  • Brad Nelson, PhD - BC Cancer-Deeley Research Center

Learn more about the 2022 Targets for Cancer IO: A Deep Dive Series here!

Targets for Cancer IO: A Deep Dive Series is supported, in part, by educational grants from Genmab, US, Inc. and Merck & Co., Inc. (as of 6/6/2022).

#TargetsforCancerImmunotherapyADeepDiveSeminarSeries #NoCEOffered #Industry #Researcher #2022
Event Image

Contact



education@sitcancer.org

Related Content